Priority review for Genentech’s flu drug
The US Food and Drug Administration will undertake a priority review of Genentech’s experimental flu drug baloxavir marboxil in people aged 12 years and older.
Read More
Tag: CAPSTONE-1
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
